Page 1666 - Clinical Small Animal Internal Medicine

1604 Index

exocrine pancreatic cancer (EPC) FAIDS see feline acquired immune prognosis 888
VetBooks.ir signalment 1293 falcine herniation 750 signalment 887
deficiency syndrome
(cont’d)
public health significance 889
prognosis 1294–1295
treatment 888
false negatives 10, 24–25
treatment 1294 false positives 10, 24 feline cardiomyopathies
exocrine pancreatic insufficiency familial glomerulopathies cardiovascular disease 119,
(EPI) 583–589 1101, 1102 123–124
antibacterials 587–589 fasciculations 769 electrocardiography 172, 172
clinical features 584–585 FAST see focused assessment with heart failure 178–179
cobalamin deficiency/ sonography for trauma feline coronavirus (FCoV) 873–876
supplementation 583, fat overload syndrome (FOS) 444 diagnosis 874–875
588–589 fatty acid oxidation 182–183 epidemiology 873
diabetes mellitus 94 FCoV see feline coronavirus etiology/pathophysiology 873
diagnosis 585–587 FCV see feline calicivirus history and clinical signs 873–874
dietary modification 589 fecal alpha‐1‐proteinase prevention 875
dysbiosis 583, 588, 622 inhibitors 633 prognosis 875
etiology 583–584 fecal examination public health implications 875
histamine‐2 receptor agonists and coccidia 1024, 1024, 1026 signalment 873
proton pump inhibitors 589 protozoal and protozoa‐like treatment 875
histopathology 586–587 infections 1019, 1019 feline cytauxzoonosis 1014–1016
pancreatic enzyme salmon poisoning disease 914 diagnosis 1015
supplementation 586–588 FECV see feline enteric coronavirus epidemiology 1015
pancreatic fecal elastase 586 feeding tubes 452, 1097–1098 etiology/pathophysiology
pancreatitis 608 feline acquired immune deficiency 1014–1015
pathogenesis 583 syndrome (FAIDS) 884 history and clinical signs 1015
prognosis 589 feline acquired skin fragility signalment 1015
routine clinical pathology 585 syndrome 1482, 1482 treatment and prognosis
signalment 584 feline acromegaly 43–48 1015–1016
treatment 587–589, 587 diagnosis 44–45 feline enteric coronavirus (FECV)
trypsin‐like etiology/pathophysiology and 782, 873–875
immunoreactivity 585–586 epidemiology 43–44 feline gastrointestinal eosinophilic
extended‐spectrum beta‐lactamase history and clinical signs 44 sclerosing fibroplasia
(ESBL) 1059 medical treatment 45–46 (FGESF) 549
external ophthalmoplegia 824–825 radiation therapy 47 feline herpesvirus (FHV‐1) 887–889
external validity 7–8 surgical treatment 46 cutaneous manifestations of
extraaxial hematomas 757 treatment 45–47 systemic disease
extracellular fluid (ECF) 357–358, feline bronchial asthma 297–303 1484, 1484
1069–1070, 1073, 1079–1085 diagnosis 298–300 diagnosis 888
extracellular matrix (ECM) 182 epidemiology 297 epidemiology 887
extracorporeal shock wave lithotripsy etiology/pathophysiology 297 etiology/pathophysiology 887
(ESWL) 1119–1120, 1145–1146, history and clinical signs history and clinical signs 887–888
1146, 1156–1157 297–298 oral cavity and salivary
extrahepatic biliary obstruction monitoring and response to glands 536–537
(EHBO) 593, 669, 669 therapy 303 prevention 889
extrahepatic cholestasis 669, 669 prognosis 303 prognosis 888
extramedullary plasmacytoma respiratory pattern‐based approach public health significance 889
(EMP) 1241–1246, 1242, to dyspnea 290 signalment 887
1283–1285 treatment 300–303 treatment 888
extranodal lymphoma 1235, 1236 feline calicivirus (FCV) 887–889 feline hyperthyroidism 75–80
exudative effusions 334, 337–338 diagnosis 888 concurrent kidney disease 79
eyes and eyelids 400, 441, 1261–1262 epidemiology 887 diagnosis 77
see also ocular etiology/pathophysiology 887 etiology/pathophysiology and
history and clinical signs 887–888 epidemiology 75–76
f oral cavity and salivary history and clinical signs
facial nerve 738–739, 826 glands 536–537 76–77, 76
FAD see flea allergy dermatitis prevention 889 prognosis 79